Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players
Executive Summary
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
You may also be interested in...
EU System ‘Not Perfect But Is Fit For Purpose’, Says EMA
The European Medicines Agency has rejected claims that industry fees and allegedly flawed methods of evaluating medicines can lead to problematic development and interpretation of evidence.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.